Flexibility enables to discriminate between ligands: Lessons from structural ensembles of Bcl-xl and Mcl-1

The proteins of Bcl-2 family, which are promising anti-cancer-drug targets, have substantial similarity in primary sequence and share homologous domains as well as similar structural folds. In spite of similarities in sequence and structures, the members of its pro- and anti- apoptotic subgroups form complexes with different type of partners with discriminating binding affinities. Understanding the origin of this discrimination is very important for designing ligands that can either selectively target a protein or could be made broad ranged as necessary. Using principal component analysis (PCA) of the available structures and from the analysis of the evolution of the binding pocket residues, the correlation has been investigated considering two important anti-apoptotic protein Bcl-xl and Mcl-1, which serve as two ideal representatives of this family. The flexibility of the receptor enables them to discriminate between the ligands or the binding partners. It has been observed that although Bcl-xl and Mcl-1 are classified as homologous proteins, through the course of evolution the binding pocket residues are highly conserved for Bcl-xl; whereas they have been substituted frequently in Mcl-1. The investigation has revealed that the Bcl-xl can adjust the backbone conformation of the binding pocket residues to a larger extent to complement with the shape of different binding partners whereas the Mcl-1 shows more variation in the side chain conformation of binding pocket residues for the same purpose.

[1]  Erinna F. Lee,et al.  Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands* , 2009, The Journal of Biological Chemistry.

[2]  Tao Zhang,et al.  A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[3]  K. Mihara Targeting and insertion of nuclear‐encoded preproteins into the mitochondrial outer membrane , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[4]  Emiko Fire,et al.  Mcl‐1–Bim complexes accommodate surprising point mutations via minor structural changes , 2010, Protein science : a publication of the Protein Society.

[5]  Becky Penhallow,et al.  Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists. , 2012, Bioorganic & medicinal chemistry letters.

[6]  Ivet Bahar,et al.  ProDy: Protein Dynamics Inferred from Theory and Experiments , 2011, Bioinform..

[7]  W. D. Fairlie,et al.  Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity. , 2011, Journal of medicinal chemistry.

[8]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[9]  D. L. Wilburn,et al.  Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. , 2008, Cancer research.

[10]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[11]  D. Andrews,et al.  Still embedded together binding to membranes regulates Bcl-2 protein interactions , 2010, Oncogene.

[12]  M. Perduca,et al.  Structural changes in the BH3 domain of SOUL protein upon interaction with the anti-apoptotic protein Bcl-xL , 2011, The Biochemical journal.

[13]  Erinna F. Lee,et al.  Mutation to Bax beyond the BH3 Domain Disrupts Interactions with Pro-survival Proteins and Promotes Apoptosis* , 2011, The Journal of Biological Chemistry.

[14]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[15]  Alexander D. MacKerell,et al.  Extending the treatment of backbone energetics in protein force fields: Limitations of gas‐phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations , 2004, J. Comput. Chem..

[16]  D. Andrews,et al.  Regulating cell death at, on, and in membranes. , 2014, Biochimica et biophysica acta.

[17]  Chang Park,et al.  Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein. , 2014, Bioorganic & medicinal chemistry letters.

[18]  A. Maity,et al.  The long unstructured region of Bcl‐xl modulates its structural dynamics , 2017, Proteins.

[19]  Sudipto Saha,et al.  Adaptability in protein structures: structural dynamics and implications in ligand design , 2015, Journal of biomolecular structure & dynamics.

[20]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[21]  H. Berendsen,et al.  Essential dynamics of proteins , 1993, Proteins.

[22]  Elizabeth J. Osterlund,et al.  BCL-2 family proteins: changing partners in the dance towards death , 2017, Cell Death and Differentiation.

[23]  C. Borner,et al.  Characterization of the signal that directs Bcl-xL, but not Bcl-2, to the mitochondrial outer membrane , 2003, The Journal of cell biology.

[24]  H. Yoon,et al.  Bh3 induced conformational changes in Bcl‐Xl revealed by crystal structure and comparative analysis , 2015, Proteins.

[25]  Yuta Tanaka,et al.  Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins. , 2013, Journal of medicinal chemistry.

[26]  Brian J Smith,et al.  De-novo designed library of benzoylureas as inhibitors of BCL-XL: synthesis, structural and biochemical characterization. , 2014, Journal of medicinal chemistry.

[27]  A. Keating,et al.  Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL. , 2010, Journal of molecular biology.

[28]  Brian A. Chauder,et al.  Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. , 2013, Journal of medicinal chemistry.

[29]  Liu Liu,et al.  Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity. , 2012, Journal of medicinal chemistry.

[30]  E. Olejniczak,et al.  Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. , 2016, Journal of medicinal chemistry.

[31]  D. Green,et al.  Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario , 2006, Cell Death and Differentiation.

[32]  David W. Andrews,et al.  Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes , 2007, Apoptosis.

[33]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[34]  Anders Friberg,et al.  Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design. , 2015, Journal of medicinal chemistry.

[35]  W. Kabsch A solution for the best rotation to relate two sets of vectors , 1976 .

[36]  Erinna F. Lee,et al.  Structure‐Guided Rational Design of α/β‐Peptide Foldamers with High Affinity for BCL‐2 Family Prosurvival Proteins , 2013, Chembiochem : a European journal of chemical biology.

[37]  S. Majumdar,et al.  Ligand Binding Swaps between Soft Internal Modes of α,β-Tubulin and Alters Its Accessible Conformational Space. , 2017, The journal of physical chemistry. B.

[38]  S. Majumdar,et al.  Dynamic and Static Water Molecules Complement the TN16 Conformational Heterogeneity inside the Tubulin Cavity. , 2016, Biochemistry.

[39]  A. Scorilas,et al.  The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias , 2011, Advances in hematology.

[40]  Rebecca SY Wong,et al.  Apoptosis in cancer: from pathogenesis to treatment , 2011, Journal of experimental & clinical cancer research : CR.

[41]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[42]  Erinna F. Lee,et al.  The Functional Differences between Pro-survival and Pro-apoptotic B Cell Lymphoma 2 (Bcl-2) Proteins Depend on Structural Differences in Their Bcl-2 Homology 3 (BH3) Domains* , 2014, The Journal of Biological Chemistry.